Evaluate is a single source provider of historic and forecasted sales information for companies and products. The data is sourced from company disclosures, government resources, and equity analyst reports. Evaluate also has Sales by Indication, Volume, Pricing, Cost per Patient, Discounting rates, Compliance, and much more. Our sales information allows users to derive insight into biotech and pharmaceutical performance.
Key data highlights
Consensus sales forecasts
In this page
Consensus sales forecasts
Drug volume and pricing information
Sales by indication
Evaluate provides product sales and consensus forecasts out to 2024. This information enables the life science community to make sound business decisions about value and opportunity. Please refer to our Consensus Sales Forecast Methodology document for more information on how we derive and calculate these values.
Below is a screenshot of the Top Drugs based on Worldwide sales in 2024 from our consensus forecast
Sales by Indication
Unique to Evaluate is our Sales by Indication information. Compiled mainly through equity analyst research and EvaluatePharma’s SbI Methodology, it reveals the indication specific dynamic behind historic and forecast product sales. From this data users can determine which indication is the most commercially important for a product or estimate the size of the branded market for a disease.
The screenshot below shows what the top products are based on Sales by Indication for non-
Another way to look at the data is at the product level. Below is a screenshot of some of the Sales by Indication information for Roche’s Avastin, which as of 2018 had 20 indications in R&D or on the market.
Drug Volume and Pricing Information
Evaluate has information on drug volume and prices. This information is available for the US, Brazilian, Japanese, and European (forecast information only available in the European Drug Forecast Add-
Below is a screenshot of the USA Sales, Number of Patients Treated and Cost per Patient for Januvia
Sales related FAQs
How does Evaluate develop the forecast estimates?
Royalty and Alliance Revenue for a product are reported separately from sales. The Royalty and Alliance Forecasts in Evaluate are generally based on sales estimates from leading brokers. Evaluate uses forecasts from up to 6 equity analysts to develop the consensus forecasts.
A. Are forecast numbers weighted?
i. No, Evaluate analysts do not weight the forecast estimates when developing the consensus forecasts
B. Are sales forecasts risk adjusted?
i. Evaluate analysts do not risk adjust sales themselves. Equity analysts whom we receive reports from tend to adjust their numbers to reflect probability to launch, withdrawal, and competition risks. However, biotech companies (especially small ones), often have their forecasts presented on a “best case” scenario due to the binary valuation of the company. In the case where both risk adjusted and non-
C. How often are sales forecasts updated?
i. Consensus forecasts are updated as part of our monthly update
D. How often are forecast years extended?
i. Consensus forecasts are usually extended by two years, once every two years. The extension is made once we have a sufficient number of forecasts from analysts, usually around May
Does Evaluate have historic and/or forecasted sales?
Forecast sales are available on a Worldwide basis and for the USA
Historic sales are available for Worldwide, USA, Japan, Brazil, and Europe
Why do I see two different numbers for sales within the same company?
When a company reports its financial's, it will disclose sales of certain key products in its portfolio. These sales figures are associated with the appropriate product in the Products Module. We can then add these up at a company level. However, as there may be additional sales which are not attributed to a specific product, then the sum of the identified product sales may be less than the total sales for a company. The difference between the Total WW Prescription (Rx) Sales for a company and the Rx Sales from Products Module is classified as ‘Other Rx and OTC’ or ‘Other (Therapy Area Name)’
What is Evaluate’s currency conversion methodology?
Historic annual sales in Evaluate are converted to different currencies using the average exchange rate over the past year. Historic quarterly sales in Evaluate are converted to different currencies using the exchange rate over the past quarter. Forecast annual sales for the current year are converted to different currencies using the average exchange rate from the start of the year. Forecast annual sales for the future years are converted to different currencies using the average exchange rate from the last month.
To determine historic annual, half-
The exchange rates used are sourced from the Sauder Business School at The University of British Columbia in Canada: http://fx.sauder.ubc.ca/
Sales by Indication -
Evaluate will use a single indication forecast if the entire company’s forecast model is based on a single broker model. For example, if 4 out of 6 analysts only provide a forecast for a single indication (e.g. NSCLC) for Product X, and the remaining 2 analysts do not provide a sales by indication forecast, Evaluate will only provide a forecast for the one indication (NSCLC in this example).
Sales by Indication -
No, if a broker has a line item for “other indication sales” in their model, the “other” amount would not be included in the sales total. Evaluate takes the percent split from the consensus forecast to build each indications forecast and apply that to the product sales. It is rare that the “other” sales would be a large value.